TWD TradeWinds, Inc. (TWD) announces today the establishment of TWD Kemtech BioX Research Fund at Harvard Medical School’s Dana-Faber Cancer Institute, with an initial term of three years.

TWD Kemtech BioX Research Fund was established to support specifically the Chemical Biology Initiative at Dana-Faber Cancer Institute.

“We are pleased and honored to play a small part in the advancement of developing innovative and effective cancer treatment at Dana-Faber Cancer Institute,” Dr. John Wang, President and CEO of TWD TradeWinds commented. “We are delighted to have this opportunity to personally support some of the brightest young scientists in their endeavor of developing breakthrough technologies and pursuit of scientific knowledge.”